

Section: Contact Information

First Name : **Elizabeth (Lieke)**

Last Name : **Feijen**

Institution : **Emma Childrens hospital/ Academical Medical Center Amsterdam**

Address 1 : **Meibergdreef 9**

Address 2 :

City : **Amsterdam**

State/Province/Region : **International Location : Noord Holland**

Country : **NL**

Zip/Postal Code : **1105 AZ**

Phone Number : **0031205661417**

Alternate Phone Number :

Email Address : e.a.feijen@amc.uva.nl

Section: Project Requirements and Description

Group: Requirements to submit AOI

A comprehensive review of previously published data has been completed. : **Yes**

The specific aims are clear and focused. : **Yes**

The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator. : **Yes**

The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months. : **Yes**

Project Title : **Anthracycline equivalent 2**

Planned research population (eligibility criteria) :

Expanded CCSS cohort, plus external cohorts: St. Jude Lifetime Cohort (AOI discussed with Dr. Melissa Hudson) and DCOG LATER cohort

Proposed specific aims :

Determine if a more appropriate anthracycline cardiotoxicity equivalence formula can be derived based on the risk of clinical heart failure among childhood cancer survivors possibly for epirubicin, idarubicin and mitoxantrone in relation to doxorubicin. This project would extend our prior work examining daunorubicin and doxorubicin equivalence.

Will the project require non-CCSS funding to complete? : **No**

If yes, what would be the anticipated source(s) and timeline(s) for securing funding? :

Group: Does this project require contact of CCSS study subjects for:

Additional self-reported information : **No**

Biological samples : **No**

Medical record data : **No**

If yes to any of the above, please briefly describe. :

Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)

Second Malignancy :

Chronic Disease : **Primary**

Psychology / Neuropsychology :

Genetics :

Cancer Control :

Epidemiology / Biostatistics : **Secondary**

Section: Outcomes or Correlative Factors

Late mortality : **Secondary**

Second Malignancy :

Group: Health Behaviors

Tobacco :

Alcohol :

Physical activity :

Medical screening :

Other :

If other, please specify :

Group: Psychosocial

Insurance :

Marriage :

Education :

Employment :

Other :

If other, please specify :

Group: Medical Conditions

Hearing/Vision/Speech :

Hormonal systems :

Heart and vascular : **Primary**

Respiratory :

Digestive :

Surgical procedures :

Brain and nervous system :

Other :

If other, please specify :

Group: Medications

Describe medications :

Group: Psychologic/Quality of Life

BSI-18 :

SF-36 :

CCSS-NCQ :

PTS :

PTG :

Other :

If other, please specify :

Group: Other

Pregnancy and offspring :

Family history :

Chronic conditions (CTCAE v3) :

Health status :

Group: Demographic

Age : **Correlative Factors**

Race : **Correlative Factors**

Sex :

Other :

If other, please specify :

Group: Cancer treatment

Chemotherapy : **Correlative Factors**

Radiation therapy : **Correlative Factors**

Surgery :

Section: Anticipated Sources of Statistical Support

CCSS Statistical Center :

Local institutional statistician : **Yes**

If local, please provide the name(s) and contact information of the statistician(s) to be involved. :

Lieke Feijen with guidance of Leontien Kremer, Eric Chow and Wendy Leisenring

Will this project utilize CCSS biologic samples? : **No**

If yes, which of the following? :

If other, please explain :

Section: Other General Comments

Other General Comments :